William C. Eckelman

William C. Eckelman's AcademicInfluence.com Rankings

William C. Eckelman

Biology

#8635

World Rank

#11742

Historical Rank

Neuroscience

#1208

World Rank

#1252

Historical Rank

biology Degrees

Download Badge

Biology

William C. Eckelman's Degrees

Bachelors Biology Stanford University

Similar Degrees You Can Earn

Best Online Bachelor's in Biology 2026

Why Is William C. Eckelman Influential?

(Suggest an Edit or Addition)

(See a Problem?)

William C. Eckelman's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Schizophrenia is associated with elevated amphetamine-induced synaptic dopamine concentrations: evidence from a novel positron emission tomography method. (1997) (1174)
NCRP report no. 93: Ionizing radiation exposure of the population of the United States: National Council on Radiation Protection and Measurements, Bethesda, Maryland (1987). US$15.00 (1988) (726)
Reduced Serotonin Type 1A Receptor Binding in Panic Disorder (2004) (356)
Preclinical evaluation of novel glutamate-urea-lysine analogues that target prostate-specific membrane antigen as molecular imaging pharmaceuticals for prostate cancer. (2009) (269)
Long-term clinical improvement in MPTP-lesioned primates after gene therapy with AAV-hAADC. (2006) (264)
A series of halogenated heterodimeric inhibitors of prostate specific membrane antigen (PSMA) as radiolabeled probes for targeting prostate cancer. (2009) (252)
Quantification of Amphetamine-Induced Changes in [11C]Raclopride Binding with Continuous Infusion (1997) (242)
The Progress and Promise of Molecular Imaging Probes in Oncologic Drug Development (2005) (228)
PET imaging of 5-HT1A receptor binding in patients with temporal lobe epilepsy (2003) (218)
First-in-Man Evaluation of 2 High-Affinity PSMA-Avid Small Molecules for Imaging Prostate Cancer (2013) (199)
Kinetic Modeling of [11C]Raclopride: Combined PET-Microdialysis Studies (1997) (196)
99mTc-Labeled Small-Molecule Inhibitors of Prostate-Specific Membrane Antigen for Molecular Imaging of Prostate Cancer (2013) (190)
Evaluation of 99mTc-DTPA for the Measurement of Glomerular Filtration Rate (1972) (173)
Glut-1 and hexokinase expression: relationship with 2-fluoro-2-deoxy-D-glucose uptake in A431 and T47D cells in culture. (1999) (168)
Imaging Neuroinflammation in Alzheimer's Disease with Radiolabeled Arachidonic Acid and PET (2008) (160)
Muscarinic acetylcholine receptors in Alzheimer's disease. In vivo imaging with iodine 123-labeled 3-quinuclidinyl-4-iodobenzilate and emission tomography. (1985) (151)
External imaging of cerebral muscarinic acetylcholine receptors. (1984) (150)
New compounds: fatty acid and long chain hydrocarbon derivatives containing a strong chelating agent. (1975) (141)
Factors influencing DTPA conjugation with antibodies by cyclic DTPA anhydride. (1983) (132)
Molecular targets. (2006) (129)
Receptor-binding radiotracers: a class of potential radiopharmaceuticals. (1979) (123)
5-HT 1A receptors are reduced in temporal lobe epilepsy after partial-volume correction. (2005) (121)
Nuclear medicine : diagnosis and therapy (1996) (120)
A neutral technetium-99m complex for myocardial imaging. (1989) (120)
Development of fluorine-18-labeled 5-HT1A antagonists. (1999) (114)
Unparalleled contribution of technetium-99m to medicine over 5 decades. (2009) (114)
Measurement of dopamine release with continuous infusion of [11C]raclopride: optimization and signal-to-noise considerations. (2000) (112)
Opioid receptor imaging with positron emission tomography and [(18)F]cyclofoxy in long-term, methadone-treated former heroin addicts. (2000) (104)
Reduced muscarinic type 2 receptor binding in subjects with bipolar disorder. (2006) (101)
Measurement of cerebral glucose metabolic rates in the anesthetized rat by dynamic scanning with 18F-FDG, the ATLAS small animal PET scanner, and arterial blood sampling. (2004) (98)
Brain incorporation of 11C-arachidonic acid, blood volume, and blood flow in healthy aging: a study with partial-volume correction. (2004) (97)
High resolution PET, SPECT and projection imaging in small animals. (2001) (96)
Muscarinic Cholinergic Receptor Measurements with [18F]FP-TZTP: Control and Competition Studies (1998) (93)
The labeling of high affinity sites of antibodies with 99mTc. (1985) (86)
Kinetic Analysis of the 5-HT2A Ligand [11C]MDL 100,907 (2000) (85)
Instant 99mTc-DTPA. (1970) (85)
Experiment assessment of mass effects in the rat: implications for small animal PET imaging. (2004) (85)
Synthesis and SAR of ⁹⁹mTc/Re-labeled small molecule prostate specific membrane antigen inhibitors with novel polar chelates. (2013) (84)
123I-MIP-1072, a Small-Molecule Inhibitor of Prostate-Specific Membrane Antigen, Is Effective at Monitoring Tumor Response to Taxane Therapy (2011) (82)
Fast 18F Labeling of a Near-Infrared Fluorophore Enables Positron Emission Tomography and Optical Imaging of Sentinel Lymph Nodes (2010) (82)
Biodistribution, radiation dose estimates, and in vivo Pgp modulation studies of 18F-paclitaxel in nonhuman primates. (2003) (80)
One-step synthesis of 18F labeled [18F]-N-succinimidyl 4-(fluoromethyl)benzoate for protein labeling. (1994) (80)
Pharmacokinetic analysis of blood distribution of intravenously administered 153Gd-labeled Gd(DTPA)2- and 99mTc(DTPA) in rats. (1990) (75)
Radiopharmaceuticals labelled with technetium. (1977) (73)
A Prospective Study of 2-[18F] Fluoro-2-Deoxy-D-Glucose/Positron Emission Tomography Scan, 99mTc-Labeled Arcitumomab (CEA-Scan), and Blind Second-Look Laparotomy for Detecting Colon Cancer Recurrence in Patients With Increasing Carcinoembryonic Antigen Levels (2001) (73)
No change in serotonin type 1A receptor binding in patients with posttraumatic stress disorder. (2005) (73)
Preparation of cyclotron-produced 186Re and comparison with reactor-produced 186Re and generator-produced 188Re for the labeling of bombesin. (2006) (71)
Brain Incorporation of [11C]Arachidonic Acid in Young Healthy Humans Measured with Positron Emission Tomography (2002) (71)
PET evaluation of [(18)F]FCWAY, an analog of the 5-HT(1A) receptor antagonist, WAY-100635. (2000) (70)
The Suitability of [11C]-α-Methyl-L-tryptophan as a Tracer for Serotonin Synthesis: Studies With Dual Administration of [11C] and [14C] Labeled Tracer (2000) (70)
Cellular Release of [18F]2-Fluoro-2-deoxyglucose as a Function of the Glucose-6-phosphatase Enzyme System* (2000) (68)
Brain incorporation of [1–11C]arachidonate in normocapnic and hypercapnic monkeys, measured with positron emission tomography (1997) (67)
L-lysine effectively blocks renal uptake of 125I- or 99mTc-labeled anti-Tac disulfide-stabilized Fv fragment. (1996) (66)
Initial results from a PET/planar small animal imaging system (1998) (66)
Technetium-labeled red blood cells. (1971) (65)
Novel polar single amino acid chelates for technetium-99m tricarbonyl-based radiopharmaceuticals with enhanced renal clearance: application to octreotide. (2010) (65)
The influence of tumor oxygenation on hypoxia imaging in murine squamous cell carcinoma using [64Cu]Cu-ATSM or [18F]Fluoromisonidazole positron emission tomography. (2007) (63)
A receptor-targeted fluorescent radiopharmaceutical for multireporter sentinel lymph node imaging. (2012) (63)
Evidence for tissue angiotensin-converting enzyme in explanted hearts of ischemic cardiomyopathy using targeted radiotracer technique. (2007) (61)
In vivo muscarinic 2 receptor imaging in cognitively normal young and older volunteers (2003) (61)
S‐[18F]Acetylcyclofoxy: a useful probe for the visualization of opiate receptors in living animals (1984) (60)
Fluorine-18 labeled mouse bone marrow-derived dendritic cells can be detected in vivo by high resolution projection imaging. (2002) (60)
Molecular Imaging and Contrast Agent Database (MICAD): Evolution and Progress (2012) (59)
Distribution of labeled bleomycin in normal and tumor-bearing mice. (1973) (58)
Optimization of the DTPA mixed-anhydride reaction with antibodies at low concentration. (1983) (57)
The chemical state of 99m Tc in biomedical products. II. The chelation of reduced technetium with DTPA. (1972) (57)
The characteristics of I-125 4-IQNB and H-3 QNB in vivo and in vitro. (1984) (54)
Rhenium tricarbonyl core complexes of thymidine and uridine derivatives. (2005) (54)
Higher in vivo muscarinic‐2 receptor distribution volumes in aging subjects with an apolipoprotein E‐ϵ4 allele (2003) (54)
Radiolabeling of antibodies. (1980) (54)
[I-125] 17α-Iodovinyl 11β-Methoxyestradiol: In Vivo and In Vitro Properties of a High-Affinity Estrogen-Receptor Radiopharmaceutical (1984) (52)
Radiolabeling with technetium-99m to study high-capacity and low-capacity biochemical systems (1995) (51)
Fluoro-, bromo-, and iodopaclitaxel derivatives: synthesis and biological evaluation. (2003) (51)
The application of receptor theory to receptor-binding and enzyme-binding oncologic radiopharmaceuticals. (1994) (50)
Clinical evaluation of radiolabeled bleomycin (BLEO) for tumor detection. (1974) (49)
Preparation of 18F-labeled muscarinic agonist with M2 selectivity. (1995) (49)
Positron-labeled angiotensin-converting enzyme (ACE) inhibitor: fluorine-18-fluorocaptopril. Probing the ACE activity in vivo by positron emission tomography. (1991) (49)
Brain Uptake of the Acid Metabolites of F-18—Labeled WAY 100635 Analogs (2003) (49)
Decreased tumor uptake of gallium-67 in animals after whole-body irradiation. (1978) (49)
Synthesis and evaluation of radioiodinated derivatives of 1-azabicyclo[2.2.2]oct-3-yl alpha-hydroxy-alpha-(4-iodophenyl)-alpha- phenylacetate as potential radiopharmaceuticals. (1984) (49)
Discussion of targeting proteins in vivo: in vitro guidelines. (2006) (49)
Comparative cellular catabolism and retention of astatine-, bismuth-, and lead-radiolabeled internalizing monoclonal antibody. (2001) (49)
Targeted imaging: an important biomarker for understanding disease progression in the era of personalized medicine. (2008) (48)
Guidelines to authors submitting papers to the international journal of radiation applications and instrumentation (1991) (48)
Kinetic Analysis of 3-Quinuclidinyl 4-[125I]Iodobenzilate Transport and Specific Binding to Muscarinic Acetylcholine Receptor in Rat Brain in vivo: Implications for Human Studies (1990) (48)
Comprehensive radiolabeling, stability, and tissue distribution studies of technetium-99m single amino acid chelates (SAAC). (2009) (47)
Measurement of Regional Rates of Cerebral Protein Synthesis with L-[1-11C]leucine and PET with Correction for Recycling of Tissue Amino Acids: II. Validation in Rhesus Monkeys (2005) (45)
Syntheses and D2 receptor affinities of derivatives of spiperone containing aliphatic halogens. (1986) (45)
Analytical Pitfalls with 99mTc-labeled Compounds (1972) (44)
Relative reactivity of DTPA, immunoreactive antibody-DTPA conjugates, and nonimmunoreactive antibody-DTPA conjugates toward indium-111. (1985) (44)
Receptor-Binding Radiotracers (1982) (44)
Semi-remote production of [64Cu]CuCl2 and preparation of high specific activity [64Cu]Cu-ATSM for PET studies (2005) (43)
(Arg15, Arg21) VIP: Evaluation of Biological Activity and Localization to Breast Cancer Tumors (1998) (43)
The Design of Site-Directed Radiopharmaceuticals for Use in Drug Discovery (1993) (42)
Extension of the single amino acid chelate concept (SAAC) to bifunctional biotin analogues for complexation of the M(CO)3(+1) Core (M = Tc and Re): syntheses, characterization, biotinidase stability, and avidin binding. (2006) (42)
Sensitivity of new radiopharmaceuticals. (1998) (41)
Synthesis, characterization, and in vitro evaluation of nitroimidazole--BATO complexes: new technetium compounds designed for imaging hypoxic tissue. (1993) (41)
Brain Serotonin Synthesis Rates in Rhesus Monkeys Determined by [11C;[alpha;-Methyl-L-Tryptophan and Positron Emission Tomography Compared to CSF 5-Hydroxyindole-3-Acetic Acid Concentrations (1998) (41)
Extra-osseous localization of 99Tcm-Sn pyrophosphate. (1975) (40)
Justifying the number of animals for each experiment. (2007) (40)
The single-pass cerebral extraction and capillary permeability-surface area product of several putative cerebral blood flow imaging agents. (1993) (40)
Vascular-Targeted Radioimmunotherapy with the Alpha-Particle Emitter 211At (2002) (39)
Imaging signal transduction via arachidonic acid in the human brain during visual stimulation, by means of positron emission tomography (2007) (39)
[125I] 3-quinuclidinyl 4-iodobenzilate: a high affinity, high specific activity radioligand for the M1 and M2-acetylcholine receptors. (1984) (39)
Targeting proteins in vivo: in vitro guidelines. (2006) (39)
Analogues of 3-quinuclidinyl benzilate. (1982) (37)
Role of radionuclide imaging in trials of antiangiogenic therapy. (2000) (37)
Chemical and biologic properties of isolated radiolabeled bleomycin preparations. (1975) (37)
Preparation of 211At-labeled humanized anti-Tac using 211At produced in disposable internal and external bismuth targets. (1998) (37)
THE DISTRIBUTION OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR ANTAGONISTS, QUINUCLIDINYL BENZILATE AND QUINUCLIDINYL BENZILATE METHIODIDE (BOTH TRITIATED), IN RAT, GUINEA PIG, AND RABBIT (1979) (36)
Chemical state of 99mTc in biomedical products. (1971) (36)
The use of PET and knockout mice in the drug discovery process. (2003) (36)
Synthesis and SAR of novel Re/99mTc-labeled benzenesulfonamide carbonic anhydrase IX inhibitors for molecular imaging of tumor hypoxia. (2013) (36)
Regional brain uptake of the muscarinic ligand, [18F]FP-TZTP, is greatly decreased in M2 receptor knockout mice but not in M1, M3 and M4 receptor knockout mice (2003) (36)
Incorporation of [1-carbon-11]palmitate in monkey brain using PET. (1995) (36)
Labeling proteins at high specific activity using N-succinimidyl 4-[18F](fluoromethyl) benzoate. (1997) (35)
Synthesis and evaluation of (17 alpha,20E)-21-[125I]iodo-19-norpregna-1,3,5(10),20-tetraene-3,17 -diol and (17 alpha,20E)-21-[125I]iodo-11 beta-methoxy-19-norpregna-1,3,5(10),20-tetraene-3,17-diol (17 alpha-(iodovinyl)estradiol derivatives) as high specific activity potential radiopharmaceuticals. (1984) (35)
Differential effects of paroxetine on raphe and cortical 5-HT1A binding: A PET study in monkeys (2005) (34)
Biodistribution and catabolism of Ga-67-labeled anti-Tac dsFv fragment. (1997) (34)
Synthesis and Evaluation of a Series of 99mTc(CO)3+ Lisinopril Complexes for In Vivo Imaging of Angiotensin-Converting Enzyme Expression (2008) (34)
Fluoro analogs of WAY-100635 with varying pharmacokinetics properties. (2000) (34)
Imaging of muscarinic receptors in the central nervous system. (2006) (33)
True radiotracers: are we approaching theoretical specific activity with Tc-99m and I-123? (2008) (33)
Specific to nonspecific binding in radiopharmaceutical studies: it's not so simple as it seems! (2009) (33)
Amphetamine-Induced Dopamine Release (2001) (33)
Comparative Chemical Structure and Pharmacokinetics of MRI Contrast Agents (1988) (33)
Synthesis, plasma clearance, and in vitro stability of protein containing a conjugated indium-111 chelate (1980) (33)
Biologically stable [(18)F]-labeled benzylfluoride derivatives. (2000) (33)
Pretargeted α Emitting Radioimmunotherapy Using 213Bi 1,4,7,10-Tetraazacyclododecane-N,N′,N″,N‴-Tetraacetic Acid-Biotin (2004) (33)
Use of 3-quinuclidinyl 4-iodobenzilate as a receptor binding radiotracer. (1985) (33)
CRHR1 Receptor binding and lipophilicity of pyrrolopyrimidines, potential nonpeptide corticotropin-releasing hormone type 1 receptor antagonists. (2002) (32)
VIP and Breast Cancer (1998) (32)
Autoradiographic visualization of corticotropin releasing hormone type 1 receptors with a nonpeptide ligand: synthesis of [(76)Br]MJL-1-109-2. (2003) (32)
Small molecule inhibitors of PSMA incorporating technetium-99m for imaging prostate cancer: Effects of chelate design on pharmacokinetics (2012) (32)
Preparation and in vivo evaluation of linkers for 211At labeling of humanized anti-Tac. (2001) (32)
Semi-automated 86Y purification using a three-column system. (2004) (31)
Radioiodinated estrogen derivatives. (1980) (31)
Accelerating drug discovery and development through in vivo imaging. (2002) (30)
Evaluation of 99mTc-DTPA prepared by three different methods. (1971) (30)
Comparative chemical structure and pharmacokinetics of MRI contrast agents. (1988) (30)
Technetium labeling of monoclonal antibodies with functionalized BATOs. 1. TcCl(DMG)3PITC. (1991) (30)
Reduced post-synaptic serotonin type 1A receptor binding in bipolar depression (2013) (30)
Three approaches to radiolabeling antibodies with 99mTc. (1989) (29)
99mTc-pyrophosphate for bone imaging. (1974) (29)
Labeling monoclonal antibodies and F(ab')2 fragments with (111In) indium using cyclic DTPA anhydride and their in vivo behavior in mice bearing human tumor xenografts. (1984) (29)
Differences in affinities of muscarinic acetylcholine receptor antagonists for brain and heart receptors. (1983) (29)
99 mTc-Labeled Small-Molecule Inhibitors of Prostate-Specific Membrane Antigen for Molecular Imaging of Prostate Cancer (2013) (29)
In vivo competition studies with analogues of 3-quinuclidinyl benzilate. (1984) (28)
Synthesis and in vivo biodistribution of F-18 labeled 3-cis-, 3-trans-, 4-cis-, and 4-trans-fluorocyclohexane derivatives of WAY 100635. (2006) (28)
Biological distribution of chemical analogs of fatty acids and long chain hydrocarbons containing a strong chelating agent. (1977) (27)
Liquid chromatography-tandem mass spectrometry identification of metabolites of two 5-HT1A antagonists, N-[2-[4-(2-methoxylphenyl)piperazino]ethyl]-N-(2-pyridyl) trans- and cis-4-fluorocyclohexanecarboxamide, produced by human and rat hepatocytes. (2001) (27)
Early imaging in heart failure: Exploring novel molecular targets (2007) (27)
A Potential Cholinergic Mechanism of Procaine's Limbic Activation* (2004) (26)
Analysis of residual solvents in 2-[(18)F]FDG by GC. (2001) (26)
In vivo functional imaging using receptor-binding radiopharmaceuticals. Technetium 99m-galactosyl-neoglycoalbumin as a model. (1993) (26)
Cobalt-labeled bleomycin--a new radiopharmaceutical for tumor localization. A comparative clinical evaluation with gallium citrate. (1975) (25)
Syntheses and biological properties of chiral fluoroalkyl quinuclidinyl benzilates. (1995) (25)
Determination of [18F]FCWAY, [18F]FP-TZTP, and their metabolites in plasma using rapid and efficient liquid-liquid and solid phase extractions. (2003) (25)
In Vitro and In Vivo Characteristics (1989) (25)
Mood stabilizer treatment increases serotonin type 1A receptor binding in bipolar depression (2013) (25)
Radiosynthesis of [18F]3-acetylcyclofoxy: a high affinity opiate antagonist. (1985) (25)
Radioassays and experimental evaluation of dose calibrator settings for 18F. (2001) (25)
Higher in vivo muscarinic-2 receptor distribution volumes in aging subjects with an apolipoprotein E-epsilon4 allele. (2003) (24)
Synthesis of 4-[18F]fluorobenzoyllisinopril: A radioligand for angiotensin converting enzyme (ACE) imaging with positron emission tomography (2001) (24)
Evaluation of 99m Tc-DTPA for the measurement of glomerular filtration rate. (1972) (24)
[77Br]-17-alpha-Bromoethynylestradiol: in vivo and in vitro characterization of an estrogen receptor radiotracer. (1982) (24)
A handbook of radioactivity measurements procedures: National Council on Radiation Protection and Measurements. NCRP Report No. 58, 2nd edn (1985). NCRP Publications, 7910 Woodmont Avenue, Bethesda, MD 20814, U.S.A. US $22 (1985) (23)
A neutral lipophilic technetium-99m complex for regional cerebral blood flow imaging. (1990) (23)
Synthesis and biological activity of fluoro-substituted pyrrolo[2,3-d]pyrimidines: the development of potential positron emission tomography imaging agents for the corticotropin-releasing hormone type 1 receptor. (2000) (23)
In vitro and in vivo characteristics of [iodine-125] 3-(R)-quinuclidinyl (S)-4-iodobenzilate. (1989) (23)
Progress using Tc-99m radiopharmaceuticals for measuring high capacity sites and low density sites. (2013) (23)
Reactions of recoiling silicon atoms with phosphine, silane, and ethylene (1968) (22)
The chemistry of technetium labeling of radiopharmaceuticals by electrolysis. (1974) (22)
[125I]17-α-Iodovinyl 11-β-Methoxyestradiol Interaction in Vivo with Estrogen Receptors in Hormone-independent MCF-7 Human Breast Cancer Transfected with the v-rasH Oncogene (1987) (22)
Estrogen derivatives for the external localization of estrogen-dependent malignancy. (1977) (22)
Evaluation of (76)Br-FBAU as a PET reporter probe for HSV1-tk gene expression imaging using mouse models of human glioma. (2005) (21)
Visualization of the human spleen with 99mTc-labeled red blood cells. (1971) (21)
Binding Characteristics and Biological Activity of 17α-[125I]Iodovinyl-11β-methoxyestradiol, an Estrogen Receptor-binding Radiopharmaceutical, in Human Breast Cancer Cells (MCF-7) (1986) (21)
The gallium-deferoxamine complex: stability with different deferoxamine concentrations and incubation conditions. (1998) (21)
Iodinated bleomycin: an unsatisfactory radiopharmaceutical for tumor localization. (1976) (21)
The classification of radiotracers. (1978) (20)
Targeting of transferrin receptors in nude mice bearing A431 and LS174T xenografts with [18F]holo-transferrin: permeability and receptor dependence. (1999) (20)
The role and regulation of cardiac angiotensin-converting enzyme for noninvasive molecular imaging in heart failure (2007) (20)
Theory and Practice of Imaging Saturable Binding Sites (2002) (20)
Technetium-99m labeling and biodistribution of anti-TAC disulfide-stabilized Fv fragment. (1997) (20)
Transchelation of 99mTc from low affinity sites to high affinity sites of antibody. (1986) (19)
Comparison of an 18F labeled derivative of vasoactive intestinal peptide and 2-deoxy-2-[18F]fluoro-D-glucose in nude mice bearing breast cancer xenografts. (2002) (19)
Radioiodinated Derivatives of β Adrenoceptor Blockers for Myocardial Imaging (1978) (19)
Quantification of Kryptofix 2.2.2 in 2-[(18)F]FDG and other radiopharmaceuticals by LC/MS/MS. (2002) (19)
Identification of metabolites of fluorine-18-labeled M2 muscarinic receptor agonist, 3-(3-[(3-fluoropropyl)thio]-1,2,5-thiadiazol-4-yl)-1,2,5,6-tetrahydro-1-methylpyridine, produced by human and rat hepatocytes. (2002) (19)
Technetium labeling of monoclonal antibodies with functionalized BATOs: 2. TcCl(DMG)3CPITC labeling of B72.3 and NP-4 whole antibodies and NP-4 F(ab')2. (1991) (18)
Technical considerations in labeling of blood elements. (1975) (18)
Quantitative analysis of tumor biochemisty using PET and SPECT. (2000) (18)
Important parameters to consider for the characterization of PET and SPECT imaging probes. (2011) (18)
Preparation and in vivo evaluation of novel linkers for 211At labeling of proteins. (2004) (18)
Aminosyn II effectively blocks renal uptake of 18F-labeled anti-tac disulfide-stabilized Fv. (1998) (18)
Vascular imaging with 99m Tc-red blood cells. (1973) (18)
Distribution of the 5-HT1A receptor antagonist [18F]FPWAY in blood and brain of the rat with and without isoflurane anesthesia (2007) (18)
The development of a potential single photon emission computed tomography (SPECT) imaging agent for the corticotropin-releasing hormone receptor type. (2001) (17)
In vivo chemistry of 99mTc-chelates. (1982) (17)
In vivo receptor binding of iodinated beta-adrenoceptor blockers. (1980) (17)
Factors influencing the in vivo pharmacokinetics of peptides and antibody fragments: the pharmacokinetics of two PET-labeled low molecular weight proteins. (1997) (17)
Evaluation of human transferrin radiolabeled with N-succinimidyl 4-[fluorine-18](fluoromethyl) benzoate. (1996) (17)
Application of LC-MS to the analysis of new radiopharmaceuticals. (2003) (17)
Calculation of binding isotherms when ligand and receptor are in different volumes of distribution. (1980) (17)
Evaluation of [76Br]FBAU 3',5'-dibenzoate as a lipophilic prodrug for brain imaging. (2002) (16)
[68Ga]Ga-P16-093 as a PSMA-Targeted PET Radiopharmaceutical for Detection of Cancer: Initial Evaluation and Comparison with [68Ga]Ga-PSMA-11 in Prostate Cancer Patients Presenting with Biochemical Recurrence (2019) (16)
Characterization of nanoparticle-based contrast agents for molecular magnetic resonance imaging (2012) (16)
The Synthesis and In Vivo Pharmacokinetics of Fluorinated Arachidonic Acid: Implications for Imaging Neuroinflammation (2012) (16)
Reversed-phase high-performance liquid chromatography of bleomycin. (1976) (16)
Systemic radioimmunotherapy using a monoclonal antibody, anti-Tac directed toward the alpha subunit of the IL-2 receptor armed with the alpha-emitting radionuclides (212)Bi or (211)At. (2004) (16)
Direct labeling with 99mTc. (1991) (16)
In vivo muscarinic binding selectivity of (R,S)- and (R,R)-[18F]-fluoromethyl QNB. (1997) (15)
Are there lessons to be learned from drug development that will accelerate the use of molecular imaging probes in the clinic? (2005) (15)
Synthesis and validation of fatty acid analogs radiolabeled by nonisotopic substitution (2007) (15)
True tracer radiolabeling of gadolinium complex of 10‐(2‐hydroxypropyl)‐1,4,7,10‐tetraazacyclododecane‐1,4,7 triacetic acid (HP‐DO3A) (1993) (15)
The use of gene-manipulated mice in the validation of receptor binding radiotracer. (2003) (15)
Semi-remote production of Br-76 and preparation of high specific activity radiobrominated pharmaceuticals for PET studies (2004) (14)
Biomedical imaging research opportunities workshop IV: a white paper. (2007) (14)
Automated synthesis of 6-[18F]fluoro-l-DOPA using modified polystyrene supports with bound 6-mercuric DOPA precursors (1998) (14)
Using single photon emission tomography (SPECT) and positron emission tomography (PET) to trace the distribution of muscarinic acetylcholine receptor (MACHR) binding radioligands. (1999) (14)
Synthesis and evaluation of an 18F analog of forskolin for imaging adenylyl cyclase (2000) (14)
[131I]MIP-1466, a small molecule prostate-specific membrane antigen (PSMA) inhibitor for targeted radiotherapy of prostate cancer (PCa) (2012) (14)
Automated synthesis of 18F analogue of paclitaxel (PAC): [18F]Paclitaxel (FPAC). (2007) (14)
Molecular nuclear medicine. The challenge of genomic and proteomics to clinical practice (2003) (13)
A Radioimmunoassay for SQ 27,519, the Active Phosphinic Acid‐Carboxylic Diacid of the Prodrug Fosinopril in Human Serum (1990) (13)
Kinetic Analysis of 3-Quinuclidinyl 4-[125] Iodobenzilate Transport and Specific Binding to Muscarinic Acetylcholine Receptor in Rat Brain In Vivo (1989) (13)
Animal Models in Radiotracer Design (2011) (13)
Radiolabeled muscarinic radioligands for in vivo studies. (2001) (13)
Device-dependent activity estimation and decay correction of radionuclide mixtures with application to Tc-94m PET studies. (2001) (13)
Receptor 1980 and Receptor 2000: twenty years of progress in receptor-binding radiotracers. (2001) (13)
Liquid chromatography-tandem mass spectrometry identification of metabolites of three phenylcarboxyl derivatives of the 5-HT(1A) antagonist, N-(2-(4-(2-methoxyphenyl)-1-piperazinyl)ethyl)-N-(2-pyridyl) trans-4-fluorocyclohexanecarboxamide (FCWAY), produced by human and rat hepatocytes. (2002) (13)
National Cancer Institute workshop statement: Advances in clinical imaging using positron emission tomography, September 14-16, 1988 (1990) (12)
Species differences in metabolites of PET ligands: serotonergic 5-HT1A receptor antagonists 3-trans-FCWAY and 3-cis-FCWAY. (2006) (12)
[76Br]BMK‐I‐152, a non‐peptide analogue for PET imaging of corticotropin‐releasing hormone type 1 receptor (CRHR1) (2009) (12)
NEW COMPOUNDS, FATTY ACID AND LONG-CHAIN HYDROCARBON DERIVATIVES CONTAINING A STRONG CHELATING AGENT (1975) (12)
Development of radiochemically pure antibodies. (1990) (12)
99m Tc-Labeled Small-Molecule Inhibitors of Prostate-Specific Membrane Antigen for Molecular Imaging of Prostate Cancer (2013) (12)
Monitoring the correction of glycogen storage disease type 1a in a mouse model using [(18)F]FDG and a dedicated animal scanner. (2002) (12)
Molecular Nuclear Medicine (2003) (11)
Evaluation of stereoisomers of 4-fluoroalkyl analogues of 3-quinuclidinyl benzilate in in vivo competition studies for the M1, M2, and M3 muscarinic receptor subtypes in brain. (1995) (11)
Splenic sequestration of 99m Tc-labeled red blood cells. (1972) (11)
The use of in vitro models to predict the distribution of receptor binding radiotracers in vivo. (1989) (11)
Reaction of Recoiling Silicon Atoms with Phosphine and Silane (1966) (11)
High-specific-activity 99m Tc Human serum albumin. (1972) (11)
Development of a simple kit for Tc-99m-MIP-1404, a single amino acid chelate (SAAC II) derived small molecule inhibitor of prostate specific membrane antigen (PSMA) for imaging prostate cancer (2012) (11)
A rapid simple improved method for the preparation of Tc99m red blood cells for the determination of red cell volume. (1973) (11)
Synthesis of [3H](4-fluorobutyl)propyl[2,5,6-trimethyl-7-(2,4,6-trimethylphenyl)pyrrolo[2,3-d]pyrimidin-4-yl]amine: a potent radioligand for corticotropin-releasing hormone type 1 receptor (2000) (11)
Radiochemical Purity of New Radiopharmaceuticals (1976) (10)
Reactions of recoiling silicon atoms with phosphine and butadiene, and the addition of silylene to butadiene (1974) (10)
Measurement of transferrin receptor kinetics in the baboon liver using dynamic positron emission tomography imaging and [18F]holo‐transferrin (1997) (10)
Comparison of 99mTc and 111In labeling of conjugated antibodies. (1986) (10)
Use of 1,8‐bis‐(dimethylamino)‐naphthalene/H18F complex as new radiofluorinating agent (2004) (10)
The status of radiopharmaceutical research. (1991) (10)
Radiochemical synthesis and biodistribution of a novel maxi-K potassium channel opener. (2002) (10)
The toxicity of Sn-pyrophosphate: clinical manifestations prior to acute LD50. (1974) (10)
Inhibition of [18F]FP‐TZTP binding by loading doses of muscarinic agonists P‐TZTP or FP‐TZTP in vivo is not due to agonist‐induced reduction in cerebral blood flow (2003) (10)
Perspective, the one most responsive to change. (2014) (10)
Imaging the renin-angiotensin-aldosterone system in the heart (2005) (10)
Why does the agonist [18F]FP-TZTP bind preferentially to the M2 muscarinic receptor? (2006) (10)
Synthesis of polymer-bound 6-mercuric carboxylate DOPA precursors and solid phase labelling method of 6-radioiodinated L-DOPA. (1996) (9)
Radiochemical synthesis of [18F]fluoropaclitaxel ([18F]FPAC) (2001) (9)
Molecular imaging and contrast agent database (MICAD): A component of the NIH Roadmap (2006) (9)
Utility of azetidinium methanesulfonates for radiosynthesis of 3‐[18F]fluoropropyl amines (2004) (9)
Chemistry and Biology of Radiotracers That Target Changes in Sympathetic and Parasympathetic Nervous Systems in Heart Disease (2015) (9)
No‐carrier‐added bromination of estrogens with chloramine‐t and Na77Br (1981) (9)
Evaluation of beta adrenoceptor antagonist affinity and cardioselectivity by radioligand-receptor assay. (1979) (9)
The sequential syntheses of [76Br]FBAU 3′,5′‐dibenzoate and [76Br]FBAU (2001) (9)
Essential parameters to consider for the characterization of optical imaging probes. (2012) (9)
Myocardial Blood Flow and Innervation Measures from a Single Scan: An Appealing Concept but a Challenging Paradigm (2015) (8)
NMR ENHANCEMENT WITH Gd LABELED ANTIBODIES (1988) (8)
Review of new clinical applications of radiometal labeled radiopharmaceuticals. (2011) (8)
Cardioselectivity of beta-adrenoceptor blocking agents. 2. Role of the amino group substituent. (1983) (8)
An automated radiopharmaceutical dispenser. (1997) (8)
Boronic acid adducts of technetium dioxime (BATO) complexes derived from quinuclidine benzilate (QNB) boronic acid stereoisomers: syntheses and studies of their binding to the muscarinic acetylcholine receptor. (1995) (8)
The use of tritium labeled compounds to develop gamma-emitting receptor-binding radiotracers. (1982) (8)
Scatchard Analysis with Bolus/Infusion Administration of [11C]Raclopride (2002) (8)
Technetium-99m-pyridoxylideneglutamate, a new agent for gallbladder imaging: comparison with 131I-rose bengal. (1976) (8)
Autoradiographic evidence that (R)-3-quinuclidinyl (S)-4-fluoromethylbenzilate ((R,S)-FMeQNB) displays in vivo selectivity for the muscarinic m2 subtype. (1996) (8)
Further discussions on choosing the number of animals for an experiment. (2008) (8)
Instant 99mTc Compounds (1971) (7)
Routine quality control of recycled target [18O]water by capillary electrophoresis and gas chromatography. (2003) (7)
Three radioligands compared for determining cytoplasmic estrogen-receptor content of human breast carcinomas. (1982) (7)
Imaging of the muscarinic acetylcholine neuroreceptor in rats with the M2 selective agonist [18F]FP-TZTP. (2012) (7)
Mechanism of Target Specific Uptake Using Examples of Muscarinic Receptor Binding Radiotracers (2005) (7)
A multi-organ, axially distributed model of capillary permeability for a magnetic resonance imaging contrast agent. (1993) (7)
Technetium-99m special issue (1982) (7)
An automated one-step one-pot [(18)F]FCWAY synthesis: development and minimization of chemical impurities. (2007) (7)
The Potential Uses of Radiopharmaceuticals in the Pharmaceutical Industry (1993) (7)
Comparison of the pharmacokinetics of different analogs of 11C-labeled TZTP for imaging muscarinic M2 receptors with PET. (2008) (7)
Rational development of radiopharmaceuticals for HIV-1. (2014) (6)
Technetium labeling of albumin. (1972) (6)
Thyroidal pertechnetate uptake in Hashimoto's disease. (1971) (6)
In vivo and in vitro characteristics of the N-methyl derivative of [125I]3-quinuclidinyl 4-iodobenzilate. (1984) (6)
Synthesis of polymer-bound 6-thiolatomercury and 6-mercuric sulfonate DOPA precursors and their halodemercuration reactivity. (1995) (6)
Trend Analysis of Quality Control Data (1995) (6)
Synthesis and screening of conformationally restricted and conformationally free N-(tertiary aminoalkyl)dithiocarbamic acids and esters as inhibitors of neuronal nitric oxide synthase. (1998) (6)
Kinetic analysis of muscarinic receptors in human brain and salivary gland in vivo. (1995) (6)
Electrophilic iodination of aromatic rings. (1984) (6)
Choosing a target for targeted radionuclide therapy using biomarkers to personalize treatment (2014) (6)
Novel imaging strategies for predicting remodeling and evolution of heart failure: targeting the Renin-Angiotensin system. (2006) (6)
SYNTHESIS AND EVALUATION OF RADIOIODINATED DERIVATIVES OF 1‐AZABICYCLO(2.2.2)OCT‐3‐YL α‐HYDROXY‐α‐(4‐IODOPHENYL)‐α‐PHENYLACETATE AS POTENTIAL RADIOPHARMACEUTICALS (1984) (6)
99m Tc-DTPA preparations. (1971) (5)
Receptor-selective localization in pancreas. (1985) (5)
Nonpeptide corticotropin releasing hormone type 1 receptor antagonists as medications and imaging agents (2002) (5)
Evidence for increased angiotensin II type 1 receptor immunoreactivity in peri-infarct myocardium of human explanted hearts (2002) (5)
The Use of Positron Emission Tomography in Drug Discovery and Development (2005) (5)
Interaction of iodinated quinuclidinyl benzilate enantiomers with M3 muscarinic receptors. (1994) (5)
What is to be gained by imaging the same animal before and after treatment? (2005) (5)
Cardioselectivity of beta-adrenoceptor blocking agents 1. 1-[(4-Hydroxyphenethyl)amino]-3-(aryloxy)propan-2-ols. (1979) (5)
Analytical pitfalls with 99m Tc-labeled compounds. (1972) (5)
Choosing a single target as a biomarker or therapeutic using radioactive probes. (2015) (5)
Evaluation of [18F]fluoroxanomeline {5-{4-[(6-[18F]fluorohexyl)oxy]-1,2,5-thiadiazol-3-yl}-1-methyl-1,2,3,6-tetrahydropyridine} in muscarinic knockout mice. (2007) (5)
Designing a molecular probe for muscarinic acetylcholine receptor (mAChR) imaging. (1995) (4)
Synthesis and evaluation of radioligands for angiotensin converting enzyme (ACE) imaging (2006) (4)
Pharmacokinetics of 99MTC-myocardial perfusion agents in different species (1989) (4)
Postmeeting summary on the round table discussion at the Seventh International Symposium on Technetium in Chemistry and Nuclear Medicine held in Bressanone, Italy on Sept 6-9, 2006. (2007) (4)
Synthesis and evaluation of radioiodinated 6-iodo-L-DOPA as a cerebral L-amino acid transport marker. (1996) (4)
Re: Receptor binding of F-18 haloperidol and spiroperidol. (1984) (4)
[I-125] 17 alpha-Iodovinyl 11 beta-methoxyestradiol: in vivo and in vitro properties of a high-affinity estrogen-receptor radiopharmaceutical. (1984) (4)
Mülhardt: Molecular biology and genomics Translated by E.W. Beese, M.D., 2006, Paperback, 300 pp. 0-12-088546-8. Academic Press. An imprint of Elsevier (2007) (4)
Purification of the precursor for the automated radiosynthesis of [18F]FCWAY by counter-current chromatography. (2004) (4)
Nuclear Imaging and Biomarkers in Drug Development Using Approved Radiopharmaceuticals (2001) (4)
Labeled Agents as Tracers and Carriers: Theory and Practice (2003) (3)
Scintigraphic and immunohistochemical evidence for localization of angiotensin converting enzyme to myocytes in human ischemic cardiomyopathy (2003) (3)
[11C]diazepam synthesis : N-[11C]methylation of desmethyldiazepam is facilitated by utilization of a preformed sodium salt/benzo-15-crown-5 complex (1999) (3)
Receptors labeled with gamma-emitting radiotracers. (1986) (3)
Proceedings: use of imaging in drug R&D (1999) (3)
Targeted molecular imaging: target significance and probe validation. (2012) (3)
The Chemical and Biological Properties of Isolated Radiolabeled Bleomycin Components (1975) (3)
The development of single-photon emitting receptor-binding radiotracers (1992) (3)
Evaluation of 99mTc-Pyridoxylideneglutamate for the Differential Diagnosis of Jaundice (1976) (3)
European Association of Nuclear Medicine Congress (2004) (3)
Tc-99m labeled red blod cells: a new radiopharmaceutical for the determination of total blood volume and blood pool scanning. (1973) (3)
Technetium-labeled red blood cells. (1971) (3)
A review of new oncotropic tracers for PET imaging. (1996) (3)
Animal Models in Biomedical Research and Radiotracer Design (1983) (3)
THE DEVELOPMENT OF MUSCARINE CHOLINERGIC RECEPTOR-BINDING RADIOTRACERS (1982) (2)
Molecular imaging and contrast agent database (MICAD): Progress and current status (2010) (2)
Principles of molecular targeting for radionuclide therapy (2017) (2)
From bench to bedside. (2003) (2)
Changes: choosing a target? (2011) (2)
SQ 32097: A potential TC-99M labeled brain imaging agent (1989) (2)
Exchange labeling of proteins:99mTc labeled transferrin (1980) (2)
Cyclotron production and potential clinical application of Iodine-124 labeled radiotracers (2001) (2)
89. A potential cholinergic mechanism of procaine's limbic activation (1998) (2)
Synthesis of doubly 13C-labelled antalarmin isotopomers for pharmacokinetic studies (2002) (2)
One of three thousand. (1981) (2)
Radiopharmaceutical space. (2006) (2)
Theoretical Analysis of Optimal Conditions in Fquilibrium Imaging of in Vivo Receptors (1985) (2)
Direct analysis of whole blood by internal surface reversed-phase chromatography: an examination of the binding and metabolism of technetium dioxime complexes. (1992) (2)
The Design of Receptor-Binding Radiotracers (2019) (2)
Targeting Prostate Cancer with Small Molecule Inhibitors of Prostate-Specic Membrane Antigen (2012) (1)
Receptors in Hormone-independent MCF-7 Human Breast Cancer Transfected with the \-rasH Oncogene (1987) (1)
18F-labeled small molecule inhibitors of prostate specific membrane antigen (PSMA) for PET imaging of prostate cancer (2012) (1)
Letter: Chemical state of technetium in vivo. (1976) (1)
Nuclear Medicine Imaging (1984) (1)
Chemical State of Technetium In vivo (Letter No. 1) (1976) (1)
Alteration of 99mTc Red Blood Cells—Authors' Reply (1972) (1)
Preface for "The quantification with FDG as seen by a physician" by Galli et al. (2013) (1)
ANALOGS OF 3-QUINUCLIDINYL BENZILATE (1983) (1)
Muscarinic cholinergic2 receptor binding in bipolar disorder: Relation to saliency of affective-words (2005) (1)
JOURNAL OF DIAGNOSTIC IMAGING IN THERAPY (2014) (1)
Evaluation of 99mTc-labeled small molecule inhibitors of carbonic anhydrase (CA) for imaging hypoxia (2012) (1)
Introduction: Diagnostic imaging in oncology, 28–30 April 1993, Naples, Italy (1994) (1)
Analogues of estradiol as potential breast tumor imaging agents (1984) (1)
Radiopharmaceutical quality assurance--pilot study. (1981) (1)
Molecular modeling of the interaction of diagnostic radiopharmaceuticals with receptor proteins: m2 antagonist binding to the muscarinic m2 subtype receptor. (1997) (1)
Preparation of a stable /sup 99m/Tc complex of F(ab')/sub 2/-DTPA and its biodistribution in mice (1984) (1)
Process for preparing iodovinyl-estradiol (1986) (1)
Diagnostic isotopes. Prospects for improved agents. (1989) (1)
Alun G. Jones PhD, 1941–2012 (2013) (1)
The past, present, and the promise of the future of nuclear medicine and biology. (2017) (1)
Recent Advances in Radiopharmaceuticals (1992) (1)
CARDIOSELECTIVITY OF β-ADRENOCEPTOR BLOCKING AGENTS. 2. ROLE OF THE AMINO GROUP SUBSTITUENT (1983) (1)
Radiolabeling of unprotected octreotide with F-18 (2001) (1)
Imaging neuroinflammation in Alzheimer disease with [1–11C] arachidonic acid and positron emission tomography (2005) (1)
Reply to: The Validity of the PET/α-[11C]Methy-L-Tryptophan Method for Measuring Rates of Serotonin Synthesis in Human Brain (1999) (1)
After bench to bedside: the impact of disease progression, commercial opportunities and available instrumentation on clinical outcome. (2007) (1)
Erratum to “What is to be gained by imagine the same animal before and after treatment?” [Nucl Med Biol 2005;32:727–32] (2006) (1)
Small molecule carbonic anhydrase IX inhibitors for targeted molecular imaging of cancer by SPECT (2009) (1)
The feasibility of recycling glass liquid scintillation vials. (1982) (1)
[α-11C]Methyl-l-tryptophan in Anesthetized Rhesus Monkeys (2001) (1)
Comparison of myocardial uptake and distribution of thallium-201 and two prototype receptor-binding radiopharmaceuticals in the normal and ischemic canine heart. (1984) (1)
[125I]17-alpha-iodovinyl 11-beta-methoxyestradiol interaction in vivo with estrogen receptors in hormone-independent MCF-7 human breast cancer transfected with the v-rasH oncogene. (1987) (1)
Oncologic Drug Development The Progress and Promise of Molecular Imaging Probes in (2005) (1)
Molecular Imaging and Contrast Agent Database (MICAD): Progress and accomplishments (2007) (1)
PET imaging of dopamine receptors in MPTP-induced parkinsonism (1984) (1)
Chemistry and Biology of Radiotracers Designed to Target Changes in the Myocardial Sympathetic and Parasympathetic Nervous Systems as a Function of Disease or Treatment (2017) (1)
Instant 99m compounds. (1971) (1)
/sup 99m/Tc-pyrophosphate for bone imaging (1974) (1)
Does Labeled |[agr]|-Methyl-L-Tryptophan Image ONLY Blood|[ndash]|Brain Barrier Transport of Tryptophan? (Reply) (2000) (1)
“Second-generation single-amino-acid chelate technology with enhanced hydrophilicity: development and successful application to molecular imaging” (2010) (0)
The development of drugs for low capacity sites by noninvasive imaging (1992) (0)
Binding characteristics and biological activity of 17 alpha-[125I]iodovinyl-11 beta-methoxyestradiol, an estrogen receptor-binding radiopharmaceutical, in human breast cancer cells (MCF-7). (1986) (0)
In vitro and in vivo quality control: Differences in metabolites of radiotracers produced by rat, monkey, and human hepatocytes, invited (2004) (0)
Gadolinium labeled antibodies for use in magnetic resonance imaging (MRI) (1986) (0)
Comparison of SSTR2 agonist and antagonist peptides incorporating a novel 99mTc-chelator for targeting neuroendocrine tumors (2011) (0)
Applications of Nuclear Imaging in Drug Discovery and Development (2006) (0)
NIH MICAD and new program initiatives (2008) (0)
Introduction (1999) (0)
Labeling of blood cells with /sup 99m/Tc (1974) (0)
Metabolites of three phenylcarboxyl derivatives of the 5‐HT1A antagonists, way 100635, produced by human and rat hepatocytes (2001) (0)
Characteristics of I-125 4-IQNB and H-3 QNB in vivo and in vitro. [Rats] (1984) (0)
Radioiodinated derivatives of beta adrenoceptor blockers for myocardial imaging. (1978) (0)
Receptorâ€”Binding Radiotracers: A Class of Potential Radiopharmaceuticais (2006) (0)
Nuclear medicine pioneer Paul Harper, 1915–2005 (2006) (0)
Synthesis and Biological Activity of Fluoro‐Substituted Pyrrolo[2,3‐d]pyrimidines. The Development of Potential Positron Emission Tomography Imaging Agents for the Corticotropin‐Releasing Hormone Type 1 Receptor. (2000) (0)
Important Chemical Variables for Labeling Antibodies with Indium-111 and Technetium-99m (1988) (0)
Synthesis of [76Br] 1-(2-fluoro-2-deoxy-3,5-O-dibenzoyl-β-D-arabinofuranosyl)-5-BRO mouracil([76Br]FBAU 3′,5′-dibenzoate) and its evaluation as a tracer for imaging brain cell proliferation (2001) (0)
Radiotracer Localization by Receptor-Ligand Interactions (2021) (0)
Influence of functionalized chelators on affinity and pharmacokinetics of 99mTc(CO)3-labeled small molecules targeting prostate specific membrane antigen (PSMA) (2010) (0)
99mTc-Labeled carbonic anhydrase IX (CA IX) inhibitors for molecular imaging of cancer (2010) (0)
Molecular targeting using advanced single amino acid chelates (SAAC) for 99mTc (2009) (0)
Future Development of Radiopharmaceuticals (1992) (0)
THE TOXICITY OF Sn-PYROPHOSPHATE: (2006) (0)
Positron emission tomography: radiochemistry. (1995) (0)
CARDIOSELECTIVITY OF β-ADRENOCEPTOR BLOCKING AGENTS. 1. 1-((4-HYDROXYPHENETHYL)AMINO)-3-(ARYLOXY)PROPAN-2-OLS (1979) (0)
Target Significance and Probe Validation * (2012) (0)
Synthesis and evaluation of a series of M(CO)3+ [M=Tc,Re] lisinopril complexes for imaging angiotensin converting enzyme (ACE) (2007) (0)
Preface: New Trends in Nuclear Oncology 27–29 September 1995, Naples, Italy (1996) (0)
Potential for imaging ovarian carcinoma by radioiodinated 11. beta. methoxy 17. cap alpha. -iodovinylestradiol (MIVE/sub 2/) (1984) (0)
99mTc-MIP-1340, a small molecule inhibitor of PSMA for molecular imaging of prostate cancer (2010) (0)
Henry N. Wagner, Jr MD (2013) (0)
Molecular imaging for monitoring prostate cancer response to paclitaxel (2010) (0)
Conference Report: 2005 MIRT Workshop (2005) (0)
Subtype selective muscarinic ligands for receptor imaging (1995) (0)
/sup 99m/Tc--DTPA RENAL STUDY. (1972) (0)
368. Muscarinic 2 receptors in cognitively normal young and old volunteers (2000) (0)
Authors' Reply (2000) (0)
The development of additional radioligands of varying pharmacokinetics for the 5‐HT1A receptor (2001) (0)
Altered distribution of (R)-quinuclidinyl I-125 4-iodobenzilate after whole body fission neutron or cobalt-60 irradiation (1984) (0)
Evaluation of 99mTc-MIP-1407, an octreotide analog for targeting neuroendocrine tumors (2010) (0)
The production of F-18 on low flux reactors (1985) (0)
A name change for the Society: perspectives. (2011) (0)
Biodistribution and pet imaging of muscarinic subtype selective 3-(3-(3-fluoropropylthio)-1,2,5-thiadiazol-4-yl)-tetrahydro-1-methyl-pyridine (FP-TZTP) and R 3-quinuclidinyl S-fluoromethyl benzilate (FMeQNB) (1997) (0)
Synthesis and Evaluation of an 18F Analogue of Forskolin for Imaging Adenylyl Cyclase. (2000) (0)
Agglutination of labeled RBC. (1972) (0)
A Muscarinic Receptor Ligand: Review of the Chemistry and Applications (1991) (0)
Comparison of tc-99m and in-111 labeling of DTPA conjugated antibodies (1986) (0)
Receptor Binding Radiotracers: Volume II (2017) (0)
Receptor Binding Radiotracers (1982) : Volume II (2017) (0)
In vivo muscarinic binding selectivity of QNB (1997) (0)
Preparation of receptor binding radiotracers (1979) (0)
Toxicity of Sn-pyrophosphate: clinical manifestations prior to acute LD$sub 50$ (1974) (0)
The development of an SAR with small molecule inhibitors of prostate specific membrane antigen (PSMA) (2008) (0)
EVALUATION OF 99mTc-DTPA FOR THE Determination of glomerular filtration rate offers one of the best ways to evaluate renal function, espe cially the rate of progression of chronic renal dis (2006) (0)
Translational Applications of Molecular Imaging and Radionuclide Therapy (2005) (0)
SYNTHESIS AND EVALUATION OF (17α,20E)-21-(125I)IODO-19-NORPREGNA-1,3,5(10),20-TETRAENE-3,17-DIOL AND (17α,20E)-21-(125I)IODO-11β-METHOXY-19-NORPREGNA-1,3,5(10),20-TETRAE# NE-3,17-DIOL (17α-IODOVINYL)ESTRADIOL DERIVATIVES) AS HIGH SPEC (1985) (0)
Evaluation of ( 18 F)fluoroxanomeline {5-{4-((6-( 18 F)fluorohexyl)oxy) (2007) (0)
SPLENIC SEQUESTRATION OF 99mTCLABELED RED BLOOD CELLS (1972) (0)
Technetium-99m Pyrophosphate for Bone Imaging. (1974) (0)
In vivo estimates of synaptic dopamine concentrations with 11C-raclopride/pet: A direct test of the dopamine hypothesis (1995) (0)
Synthesis and SAR of novel 99mTc/Re(CO)3 labeled benzenesulfonamide (BzSA) conjugates targeting carbonic anhydrase IX (CA IX) (2012) (0)
Studies with I-125-MIVE/sub 2/ in human breast cancer cells (MCF-7) (1985) (0)
Targeted Optical Molecular Imaging with Cytate: From Bench toward Bedside (2012) (0)
Preclinical evaluation of a series of 99mTc-labeled carbonic anhydrase IX (CA IX) inhibitors for the detection of solid tumors (2012) (0)
Contrast media and radiopharmaceutical agents: regulatory issues. (1995) (0)
The Testing of Putative Receptor Binding Radiotracers in vivo (2021) (0)
Targeted Radiopharmaceuticals: Advances in Radiopharmacology and Radiopharmacy (2012) (0)
Radioimpurity profile of Tc-99m-MIP-1404, a single amino acid chelate derived inhibitor of prostate specific membrane antigen (PSMA) for imaging prostate cancer (2012) (0)
TH-E-330D-01: BIROW - Biomedical Imaging Research Opportunities Workshop: Intersociety Project to Accelerate Biomedical Imaging Discovery and Application - Part II (2006) (0)
Radiolabeling of Antibodies 1 (2006) (0)
Design and evaluation of novel glutamate-urea heterodimers that target PSMA as molecular imaging agents for prostate cancer. (2007) (0)
Radiolabeled Adrenergic and Muscarinic Blockers for in Vivo Studies (2019) (0)
Targeted Molecular Imaging in Cardiology (2007) (0)
In vivo chemistry of technetium chelates (1981) (0)
Technetium-99m Pyrophosphate: Comparison of ED50 for Tetany and Acidosis with Acute LD500 (1974) (0)
Molecular imaging of tumor carbonic anhydrase (CA) with a 99mTc-labeled small molecule inhibitor (2011) (0)
Development of Radiochemically Pure Antibodies 1 (2006) (0)
The use of animal models in the development of radiopharmaceuticals (1989) (0)
In vitro and in vivo properties of (/sup 125/I) (R,S) 4IQNB: A lower affinity diastereomeric muscarinic receptor radiotracer (1985) (0)
Radiopharmaceuticals for tomographic imaging of the brain. (1988) (0)
Small molecule PSMA inhibitors for targeted molecular imaging of prostate cancer (2008) (0)
Changes over the years in radiopharmaceutical design. (2019) (0)
Targeted Molecular Imaging (2012) (0)
RADIOCHEMISTRY AND RADIOPHARMACEUT1CALS RadioiodinatedEstrogenDerivatives (2006) (0)
Evaluation of [76Br]BMK-152 non-peptide analogues for corticotropin-releasing hormone type 1 receptor (CRHR1) (2006) (0)
Nuclear Imaging and Biomarkers in Drug Development Using Approved Radiopharmaceuticals (2001) (0)
Nuclear medicine pioneer Katherine Austin Lathrop, 1915-2005 (2005) (0)
The effect of chemical modification on the immunologic activity of Fab 96. 5 (1985) (0)
Michael J. Welch PhD, 1939-2012 (2012) (0)
Modern Imaging Technology: Recent Advances (2004) (0)
Further information on the aims and scope of nuclear medicine and biology (2012) (0)
Comparison of the brain pharmacokinetics (PK) of different derivatives of 11C-labeled TZTP for imaging muscarinic M2 receptors (2007) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With William C. Eckelman?

William C. Eckelman is affiliated with the following schools:

William C. Eckelman's Academic­Influence.com Rankings